A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2
222
about 5.5 years
1.00207396455779–46
130 sites in AL, AR, AZ +41
About this study
This trial is testing a treatment with blinatumomab, dasatinib or imatinib, and standard chemotherapy for children, adolescents, and young adults with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-Like) B-cell acute lymphoblastic leukemia (B-ALL). The goal is to see if combining these treatments improves outcomes compared to using dasatinib or imatinib alone with chemotherapy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Blinatumomab
- 2.Receive Radiation Therapy
- 3.Take Calaspargase Pegol
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
blinatumomab, calaspargase pegol, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), cytarabine, dasatinib, daunorubicin, doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), imatinib (Tyrosine kinase inhibitor; blocks BCR-ABL oncogene signal)
injection, intravenous, infusion, injection (Injection), oral (Oral Tablet), oral (Disintegrating Oral Tablet), oral
Primary: ABL-class Ph-like B-ALL 3-year event free survival (EFS), Incidence of adverse events, Philadelphia chromosome-positive (Ph+) (BCR::ABL1-rearranged) 3-year event free survival (EFS)
Secondary: 3-year EFS, 3-year disease free survival, 3-year overall survival (OS), OS of patients with ABL-class Ph-like B-ALL
diagnostic, biopsy, imaging, radiation
Oncology